全文获取类型
收费全文 | 526516篇 |
免费 | 28119篇 |
国内免费 | 482篇 |
专业分类
耳鼻咽喉 | 6675篇 |
儿科学 | 16882篇 |
妇产科学 | 12536篇 |
基础医学 | 92116篇 |
口腔科学 | 12325篇 |
临床医学 | 48120篇 |
内科学 | 94460篇 |
皮肤病学 | 11856篇 |
神经病学 | 33772篇 |
特种医学 | 19738篇 |
外国民族医学 | 53篇 |
外科学 | 77855篇 |
综合类 | 7604篇 |
现状与发展 | 2篇 |
一般理论 | 107篇 |
预防医学 | 38316篇 |
眼科学 | 11843篇 |
药学 | 41306篇 |
1篇 | |
中国医学 | 1075篇 |
肿瘤学 | 28475篇 |
出版年
2019年 | 3890篇 |
2018年 | 5734篇 |
2017年 | 4127篇 |
2016年 | 4872篇 |
2015年 | 5360篇 |
2014年 | 7116篇 |
2013年 | 10500篇 |
2012年 | 15574篇 |
2011年 | 17392篇 |
2010年 | 9957篇 |
2009年 | 8823篇 |
2008年 | 15714篇 |
2007年 | 17444篇 |
2006年 | 16940篇 |
2005年 | 16261篇 |
2004年 | 15872篇 |
2003年 | 15236篇 |
2002年 | 14767篇 |
2001年 | 22388篇 |
2000年 | 22907篇 |
1999年 | 18804篇 |
1998年 | 4978篇 |
1997年 | 4079篇 |
1996年 | 4119篇 |
1995年 | 4103篇 |
1992年 | 14397篇 |
1991年 | 15817篇 |
1990年 | 15944篇 |
1989年 | 15620篇 |
1988年 | 14301篇 |
1987年 | 14187篇 |
1986年 | 13162篇 |
1985年 | 12677篇 |
1984年 | 9385篇 |
1983年 | 7991篇 |
1982年 | 4163篇 |
1979年 | 8923篇 |
1978年 | 6363篇 |
1977年 | 5130篇 |
1976年 | 5492篇 |
1975年 | 6603篇 |
1974年 | 7413篇 |
1973年 | 7155篇 |
1972年 | 6592篇 |
1971年 | 6307篇 |
1970年 | 5884篇 |
1969年 | 5460篇 |
1968年 | 5158篇 |
1967年 | 4618篇 |
1966年 | 3962篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
31.
Javad Sharifi‐Rad Shahira M. Ezzat Mahitab H. El Bishbishy Dima Mnayer Farukh Sharopov Ceyda S. Kl Monica Neagu Carolina Constantin Mehdi Sharifi‐Rad Maria Atanassova Silvana Nicola Giuseppe Pignata Bahare Salehi Patrick V. T. Fokou Natlia Martins 《Phytotherapy research : PTR》2020,34(7):1474-1518
Rosmarinus species are aromatic plants that mainly grow in the Mediterranean region. They are widely used in folk medicine, food, and flavor industries and represent a valuable source of biologically active compounds (e.g., terpenoids, flavonoids, and phenolic acids). The extraction of rosemary essential oil is being done using three main methods: carbon dioxide supercritical extraction, steam distillation, and hydrodistillation. Furthermore, interesting antioxidant, antibacterial, antifungal, antileishmanial, anthelmintic, anticancer, anti‐inflammatory, antidepressant, and antiamnesic effects have also been broadly recognized for rosemary plant extracts. Thus the present review summarized data on economically important Rosmarinus officinalis species, including isolation, extraction techniques, chemical composition, pharmaceutical, and food applications. 相似文献
32.
33.
Hui Yu Zhengming Chen Karla V. Ballman Mark A. Watson Ramaswamy Govindan Irena Lanc David G. Beer Raphael Bueno Lucian R. Chirieac Michael Herman Chui Guoan Chen Wilbur A. Franklin David R. Gandara Carlo Genova Kristine A. Brovsky Mary-Beth M. Joshi Daniel T. Merrick William G. Richards Fred R. Hirsch 《Journal of thoracic oncology》2019,14(1):25-36
Objectives
Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC.Methods
A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens.Results
The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were independently prognostic for patient outcomes.Conclusions
Evaluation of PD-L1 expression, TMB, and T-effector and IFN-γ gene signatures in the cohort with early-stage SqCLC found them to be independent of each other, and none was associated with overall survival. Our results also support the hypothesis that PD-L1 expression is regulated by an intrinsic mechanism on TCs and an adaptive mechanism on immune cells. 相似文献34.
de Morais Pollyana C. V. Gama Allyne F. Fernandes Gabrielle M. Oliveira Andre H. B. Lima Marcielly F. B. dos Santos Felipe R. Martins Davi A. Nascimento Ronaldo F. Cavalcante Rivelino M. 《Bulletin of environmental contamination and toxicology》2019,102(1):66-76
Bulletin of Environmental Contamination and Toxicology - This work describes the development of an analytical protocol combining cleanup by liquid–solid extraction and GC–MS for the... 相似文献
35.
36.
Renuka V. Iyer MD Bhavana Konda MD MPH Christos Fountzilas MD Sarbajit Mukherjee MD MS Dwight Owen MD MS Kristopher Attwood PhD Chong Wang MA Orla Maguire PhD Hans Minderman PhD Sheryl-Ann Suffren BA Karen Hicks BS John Wilton PhD Robert Bies PhD Danielle Casucci BA Diane Reidy-Lagunes MD Manisha Shah MD 《Cancer》2020,126(16):3689-3697
37.
38.
K. Seejore G.E. Gerrard V.M. Gill R.D. Murray 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(4):219-224
Aims
The 2014 British Thyroid Association thyroid cancer guidelines recommend lifelong follow-up of thyroid cancer patients. This is probably unnecessary, can cause patient anxiety, is time consuming and places significant demand on National Health Service resources. It has been suggested that low-risk differentiated thyroid cancer (DTC) patients could be discharged to primary care once they are 5 years from diagnosis and treatment. The aim of this study was to investigate the potential safety of this practice.Materials and methods
In total, 756 patients with dynamically risk-stratified (DRS) low-risk/excellent response to treatment DTC treated over 2001–2013 in the Leeds region were followed after diagnostic surgery and the recurrence rate calculated.Results
The median follow-up time was nearly 10 years (5–17 years). Radiological recurrence occurred in 13/756 (1.7%) patients and was always preceded by raised thyroglobulin/ thyroglobulin antibody levels. In all 13 patients elevation of thyroglobulin occurred within 5 years of diagnosis. Two additional patients were found to have rising thyroglobulin at almost 9 and 10.5 years from diagnosis, although to date radiological recurrence has not been detected. Assuming these two patients developed recurrence with longer duration of follow-up, then 0.26% (2/756) of patients would not have their recurrence discovered within 5 years of diagnosis. To detect 100% of patients with a putative recurrence in our cohort would require 10.5 years of follow-up. Four patients had transiently raised thyroglobulin, which became undetectable within 2 years (in three patients), without any treatment and radiological recurrence was not discovered.Conclusion
Discharge of DRS low-risk DTC patients to primary care after 5 years of secondary care follow-up is reasonable, accepting that late recurrence may occur in a very small minority of individuals (0.26%, ~1:400). A more cautious approach would be to continue monitoring for 10 years, although the frequency of assessments could be reduced with increasing duration of follow-up. 相似文献39.
40.